Karyopharm Therapeutics | KPTI - 营业利润



金融业
股票价格
USD
资产
USD 108.42M
现金及等价物
USD 60.54M
销售成本
USD 1.48M
流动资产
USD 103.15M
流动负债
USD 92.06M
债务
USD 299.23M
股息收益率
0
EBIT
USD -17.84M
EBITDA
USD -26.2M
员工
325
EPS每股收益
USD -2.22
股本和储备
USD -292.93M
销售毛利
USD 32.6M
债务利息支出
USD 12.62M
利息收入
USD -0.15
贷款资金
USD 278.22M
市值
USD 1.09B
净收入
USD -102.2M
营业费用
USD 51.92M
营业利润
USD -17.84M
普通股股本
USD 18.31M
税前利润
USD -39.9M
销售收入
USD 34.08M
销售和管理费用
USD 9.56M
股票
USD 4.04M
贸易债权人
USD 4M
应收帐款人
USD 26.18M


营业利润 更改 日
AbbVie USD 4.73B 1.08B 2026-03
Abbott USD 1.85B 399M 2026-03
Amgen USD 3.83B 130M 2026-03
AstraZeneca USD 7.11B 4.14B 2026-03
BioCryst Pharmaceuticals USD 260.38M 230.79M 2025-12
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Eli Lilly USD 9.78B 792M 2026-03
Enanta Pharmaceuticals USD -23.54M 98.15M 2024-12
GlaxoSmithKline GBP 2.29B 856M 2026-03
Incyte USD 324.17M 59.7M 2026-03
J&J USD 6.62B 1.03B 2026-03
Karyopharm Therapeutics USD -17.84M 13.44M 2025-12
MacroGenics USD -12.1M 30.74M 2025-12
Merck USD -1.88B 8.12B 2026-03
Nektar Therapeutics USD -19.09M 15.26M 2025-12
Novartis USD 4.24B 171M 2026-03
Novartis USD 4.06B 521M 2025-12
Pfizer USD 4.99B 340M 2026-03
Regeneron Pharmaceuticals USD 744.8M 153.8M 2026-03
Roche Holding CHF 9.56B 3.8B 2025-12
Sangamo BioSciences USD -33.51M 12.77M 2024-06
Takeda JPY -13.62B 182.44B 2026-03
Tectonic Therapeutic USD -21.52M 374K 2025-12
TG Therapeutics USD 34.8M 15.7M 2026-03
Ultragenyx Pharmaceutical USD -216M 102M 2026-03
Xencor USD -77.86M 24.23M 2026-03